

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| Application No.: 10/554,036                   | Applicant: Yevgeni Besidski                         |
|---|---|
| Filing Date: October 20, 2005                 | Attorney Docket No.: 101023-1P US                   |
| Examiner: Laura Lynne Stockton                | Group Art Unit: 1626                                |
| Customer No.: 22466                           | Confirmation No.: 7802                              |
| Title: Heterocyclic Amides Exhibiting a (vr1) | and Inhibitory Activity at the Vanilloid Receptor 1 |

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## RESPONSE TO RESTRICTION REQUIREMENT

Sir:

Responsive to the restriction requirement dated July 23, 2008, Applicants elect Group II. We elect the single species in example 10, (4-Bromo-N-[2-(hydroxymethyl)-1,3-benzothiazol-5-yl]-2-methylbenzamide).

Applicants expressly reserve the right to prosecute claims of the non-elected inventions in future divisional or continuation applications.

Applicants believe that no fees are due; however, if any fees are due, authorization is given to charge Deposit Account 260166 for the required fees.

Applicants earnestly solicit prompt examination on the merits.

Respectfully submitted,

Name:

Karen H. Kondrad

Dated:

August 25, 2008

Reg. No.: Phone No.:

38,212 886-8975

Global Intellectual Property, Patents

AstraZeneca

1800 Concord Pike,

Wilmington, DE-19850-5437